Towards model-informed precision dosing of clofazimine, moxifloxacin, and terizidone/cycloserine in the treatment of drug-resistant tuberculosis: An external model evaluation study
Abstract
Clofazimine, moxifloxacin and terizidone/cycloserine play an important role in the treatment of drug-resistant tuberculosis (DR-TB). Personalized therapy guided by model-informed precision dosing (MIPD) can be a powerful tool to improve treatment outcomes, minimize adverse effects and combat the emergence of resistance. To set up an MIPD workflow, a population pharmacokinetic model (popPK model) is required. In this study, an external evaluation of popPK models of the three aforementioned drugs was carried out, using pharmacokinetic data from a cohort of patients with DR-TB, in order to identify the model with the best predictive performance. The best performing models (Abdelwahab et al. for clofazimine, Chirehwa et al. for moxifloxacin and Mulubwa and Mugabo for terizidone/cycloserine) were selected to calculate the area under the concentration-time curve (AUC, total exposure). An interoccasion variability (IOV, variability across dosing occasions) of AUC was quantified (13.4%CV (clofazimine), 16.1%CV (moxifloxacin), 14.5%CV (cycloserine)) indicating that using samples from one dosing occasion for AUC calculations may be sufficient to guide potential dose adjustment. Various single sampling schemes to estimate AUC were evaluated, but a unified timepoint for all drugs could not be determined. Known pharmacodynamic targets (AUC0-24h/MIC, or T>MIC) were attained in almost all patients and dosing occasions.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.